MRP1 protein expression in leukemic stem cells as a negative prognostic marker in acute myeloid leukemia patients

Autor:	Maria Podolak-Dawidziak, Aleksandra Bielawska-Pohl, Maria Paprocka, Joanna Rossowska, Olga Haus, Kazimierz Kuliczkowski, Danuta Duś, Marek Kielbinski, Agnieszka Krawczenko
Rok vydání:	2017
Předmět:	Adult Male 0301 basic medicine medicine.medical_treatment Population CD34 Gene Expression Bone Marrow Cells Immunophenotyping Flow cytometry 03 medical and health sciences 0302 clinical medicine hemic and lymphatic diseases Antineoplastic Combined Chemotherapy Protocols Biomarkers Tumor medicine Humans education Aged Aged 80 and over education.field_of_study Chemotherapy biology medicine.diagnostic_test Myeloid leukemia Hematology General Medicine Middle Aged Flow Cytometry Prognosis Leukemia Myeloid Acute Treatment Outcome 030104 developmental biology medicine.anatomical_structure 030220 oncology & carcinogenesis Immunology Neoplastic Stem Cells biology.protein Cancer research Female sense organs Bone marrow Multidrug Resistance-Associated Proteins Antibody Stem cell
Zdroj:	European Journal of Haematology. 99:415-422
ISSN:	0902-4441
Popis:	Background It is well established that expression of multi-drug resistance (MDR) proteins (MDR1, BCRP, MDR3, MRP1 and LRP) in leukemic blasts correlates with AML patients clinical response. Assuming that leukemic stem cells (LSC) are resistant to chemotherapy and responsible for relapse it might be clinically relevant to evaluate the expression level of MDR proteins in LSC and relate it to the clinical outcome. Methods Bone marrow samples from 26 patients with de novo AML were labeled with antibodies to distinguish CD34+CD38-CD123+ LSC population and with antibodies against MDR1, BCRP, MDR3, MRP1 or LRP proteins. Multicolor flow cytometry was applied to evaluate the expression of MDR proteins in blasts and LSC. Results Nine of 26 patients with AML attained CR (30%). High negative correlation was found between MDR1 and LRP expression in blasts and the patients remission. MDR proteins were expressed more frequently in LSC than in leukemic blasts. High negative correlation was also observed between remission achievement and MRP1 expression in LSC. Conclusions Our data presents for the very first time the high negative correlation between MRP1 protein expression in LSC and AML patients’ remission. It does strongly suggest that MRP1 expression in LSC is an adverse prognostic marker in patients with de novo AML. This article is protected by copyright. All rights reserved.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4ad945ee6d40150e0eae94c5a9f1703 https://doi.org/10.1111/ejh.12938 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.